In particular it is necessary to develop drugs based on the inflammatory processes that regulate and BMS 794833 destructive. There were few therapeutic advances in the pharmacological treatment of COPD, in contrast to the tremendous advances in the treatment of asthma reflect a much better amplifier Ndnis the underlying disease.1 3 develops Although COPD is usually treated with medication for asthma, the h frequently is inappropriate because the inflammatory processes in the two conditions markedly.4 5 Recognition of the importance of the global increase in the Pr prevalence of COPD and distinguish the lack of effective treatments has led to a concerted effort to develop new drugs for develop this disease.
6 7 treatment, h hangs on the rational amplifier ndnis of the underlying disease processes involved and there recent progress in reinforcing ndnis the cellular Ren and molecular mechanisms that m may receive. COPD includes chronic inflammation of the small airways and lung parenchyma, with the participation of neutrophils, macrophages and cytotoxic T lymphocytes. This inflammation causes fibrosis then with a narrowing of the airways and lung parenchyma atomizer up small because of the action of various proteases like neutrophil elastase and matrix metalloproteinases. This inflammation is seen in sharp contrast to asthma, suggesting that different treatments k Can be necessary4 discovery of new drugs for COPD, there are several reasons why drug development in COPD may be difficult.
Just recently, there was no interest for research in molecular and cellular biology of COPD to identify new therapeutic targets.8 There are no satisfactory animal models for COPD drug testing at the beginning, 9, 10 and there are uncertainties about the fa is to test drugs for COPD, long-term studies in a relatively large number of patients may require s. In addition, there is little information on surrogate markers to monitor the short-term efficacy of new therapies. However, progress has been made and several classes of drugs are currently in the pr Clinical and clinical development.6 11 cigarettes Raucherentw STATEMENTS the prim Re cause of COPD is worldwide and Raucherentw STATEMENT This is the only therapeutic intervention showed a reduction of progression the disease.
Nikotinabh Dependence, the main problem and the treatment should be with this dependence Deal addiction. The main Ans PageSever behavioral Ans tze And nicotine replacement therapy involved, but overall prices are leaving small.12 An important advance was the discovery that the antidepressant bupropion is given as a short course treatment is the most effective so far described, ending with accrued rate of 18 to 12 months, compared with 9 are nicotine patches and 6 with placebo.13 results in patients with COPD similar.14 This does not seem to be a general effect of antidepressants but nortryptiline has some effect.15 bupropion tolerated without insomnia form but Anf ll come in about 0.1 patients, especially those with previous epilepsy.16 in the future, k can effective drugs result of a better amplifier ndnisses the neurotransmitter involved besides nicotine, and progress is likely to come from research in neuroscience. N